April 17, 2026 04:32 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bengal SIR: Supreme Court allows voters restored by tribunal till April 21 and 27 to vote | 'Women won't spare you': PM Modi warns Opposition over resistance to quota bill | Vijay booked in 3 cases over poll code violation ahead of Tamil Nadu polls | 'Black law': Stalin burns copy of 'delimitation' bill, slams Modi govt | TCS halts Nashik BPO operations amid sexual abuse, conversion allegations | ‘We are surprised’: SC stays Pawan Khera’s bail over remarks on Himanta Biswa Sarma’s wife | Historic shift: Bihar gets first BJP CM as Samrat Choudhary takes oath | 'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping

Government to roll out new drug for treatment of drug-resistant TB

| | Mar 21, 2016, at 08:09 pm
New Delhi, Mar 21 (IBNS) The central government is launching a drug called Bedaquiline on Monday for the treatment of multi-drug resistant tuberculosis (MDR TB) and extensively drug resistant tuberculosis (XDR TB), according to media reports.
Dubbed a 'miracle drug',  Bedaquiline (trade name Sirturo) is the first TB drug to be approved by Food and Drug Administration (FDA) in over 40 years.
 
The project is part of a coordinated programme between the government and Johnson & Johnson and has been rolled out under the Revised National Tuberculosis Control Programme; Janssen, a pharma unit under Johnson & Johnson  has manufactured the drug.
 
The drug will be made available in six public hospitals in Delhi, Mumbai, Chennai, Guwahati and Ahmedabad, according to reports.
 
In an exclusive interview to Times of India, Sanjiv Navangul, Janssen India MD, said, "We are ready with the roll-out of the drug through the government-run control programme, for which 600 patients will be enrolled across the country, over the next six to nine months, after the required tests. Upon the review of clinical data after two years, the access programme will be expanded nationwide."
 
As per World Health Organisation (WHO) Global Tuberculosis Report 2015, deaths due to TB were estimated in India to be 2,20,000 in 2014, which is higher than any other country.
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.